Samarth Kulkarni - Mar 10, 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Mar 10, 2023
Transactions value $
-$408,170
Form type
4
Date filed
3/14/2023, 05:47 PM
Previous filing
Mar 1, 2023
Next filing
Mar 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +11.8K +3.15% 388K Mar 10, 2023 Direct F1
transaction CRSP Common Shares Tax liability -$232K -5.36K -1.38% $43.22 382K Mar 13, 2023 Direct F2
transaction CRSP Common Shares Options Exercise +9K +2.35% 391K Mar 11, 2023 Direct F1
transaction CRSP Common Shares Tax liability -$177K -4.09K -1.04% $43.22 387K Mar 13, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -11.8K -100% 0 Mar 10, 2023 Common Shares 11.8K Direct F1, F3
transaction CRSP Stock Option (Right to Buy) Award $0 +188K $0.00 188K Mar 10, 2023 Common Shares 188K $43.22 Direct F4
transaction CRSP Restricted Stock Units Award $0 +77K $0.00 77K Mar 10, 2023 Common Shares 77K Direct F1, F5
transaction CRSP Restricted Stock Units Options Exercise -9K -33.33% 18K Mar 11, 2023 Common Shares 9K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on March 10, 2020 with respect to 35,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
F4 This option was granted on March 10, 2023 with respect to 188,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023.
F5 This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
F6 This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.